Related Experiment Videos
Molecular predictors of response to chemotherapy in lung cancer
Rafael Rosell1, Miquel Taron, Aurelio Ariza
1Medical Oncology Service, the Pathology Department, Hospital Germans Trias i Pujol, Insitut Català d'Oncologia, Badalona (Barcelona), Spain.
Abstract:
Overall, chemotherapy falls short of the high expectations for improved survival in surgically resected non-small cell lung cancer patients and prolonged survival in the metastatic setting. Conventional chemotherapy trials, even those including new cytotoxic drugs or novel targeting approaches, are hampered by a lack of genetic information. Within the global genomic repair pathway, overexpression of excision repair cross-complementing 1 (ERCC1) has been associated with poor response and survival in cisplatin-treated patients. The lack of DNA adducts in cell nuclei indicates an efficient global genomic repair pathway, which leads to cisplatin resistance. Several xeroderma pigmentosum (XP) genes, including XPD, play an important role in determining the efficiency of the transcription-coupled repair pathway. XPD polymorphism has been related to lower DNA repair capacity and enhanced cisplatin sensitivity. Other DNA repair systems are the base excision repair pathway, in which apurinic/apyrimidinic endonuclease 1 (Ape 1) plays a pivotal role, and the one-step repair pathway, where O(6-)alkylguanine-DNA alkyltransferase (MGMT) has a key function. MGMT methylation can be assessed in serum DNA. By assessing ERCC1 mRNA, cisplatin adducts, XPD polymorphism, Ape 1, and MGMT, we can obtain a complete genetic profile, which can be used in real translational research.
Insights
Chemotherapy effectiveness in lung cancer is limited by genetic factors. Assessing DNA repair genes like ERCC1 and XPD can predict treatment response and improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chemotherapy offers limited survival benefits for non-small cell lung cancer (NSCLC) patients, both in resected and metastatic stages.
- Conventional chemotherapy lacks genetic information, hindering personalized treatment strategies.
- DNA repair pathways significantly influence chemotherapy response and resistance.
Purpose of the Study:
- To investigate the role of specific DNA repair genes in predicting chemotherapy response in NSCLC.
- To establish a comprehensive genetic profile for personalized lung cancer treatment.
- To explore the translational potential of genetic markers in clinical settings.
Main Methods:
- Assessing excision repair cross-complementing 1 (ERCC1) mRNA levels.
- Quantifying cisplatin-DNA adducts in cell nuclei.
- Analyzing xeroderma pigmentosum (XP) gene D (XPD) polymorphism.
- Evaluating apurinic/apyrimidinic endonuclease 1 (Ape 1) expression.
- Measuring O(6-)alkylguanine-DNA alkyltransferase (MGMT) methylation in serum DNA.
Main Results:
- Overexpression of ERCC1 is linked to poor response and survival in cisplatin-treated patients.
- Efficient global genomic repair, indicated by a lack of DNA adducts, correlates with cisplatin resistance.
- XPD polymorphism is associated with reduced DNA repair capacity and increased cisplatin sensitivity.
- A comprehensive genetic profile including ERCC1, cisplatin adducts, XPD, Ape 1, and MGMT can be generated.
Conclusions:
- Genetic profiling of DNA repair pathways offers a promising approach for personalized NSCLC treatment.
- Identifying biomarkers like ERCC1, XPD, Ape 1, and MGMT can guide chemotherapy selection and improve patient outcomes.
- Translational research incorporating these genetic markers can advance the clinical application of targeted therapies.
